Award

The divergent roles of mono- and biallelic TP53 mutations in leukemogenesis

Description: The fundamental tumor suppressor p53 – encoded by its gene TP53 – is the most frequently mutated gene in human cancer with approximately 50% of tumors across all disease subtypes being altered. TP53 mutations are associated with highly aggressive neoplasms and severely reduced patient survival. Unlike other tumor suppressors, TP53 is not inactivated by frame-shift mutations or deletions but carries, in the vast majority of cases, missense mutations leading to the expression of an aberrant p53 variant. We have recently demonstrated that a dominant-negative effect drives the selection of TP53 missense mutations in myeloid neoplasms, i.e. acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). These monoallelic TP53 mutations generally occur very early during leukemogenesis, i.e. already at the pre-malignant stage, resulting in the expansion of the mutated blood cell clone which is termed clonal hematopoiesis. Intriguingly, accumulating evidence indicates that myeloid neoplasms with biallelic TP53 mutations may represent a distinct molecular and clinical entity characterized by enhanced genomic instability and excessively poor prognosis compared to myeloid neoplasms with monoallelic TP53 mutations. These data suggest a divergent functional role of mono- and biallelic TP53 mutations in myeloid neoplasms. Therefore, we hypothesize that monoallelic TP53 mutations primarily induce clonal expansion of pre-malignant blood cell clones but are only relatively mildly pro-leukemogenic themselves. By contrast, subsequent inactivation of the remaining wild-type allele leading to biallelic loss of wild-type p53 activity results in a strongly pro-leukemogenic state characterized by genomic instability and development of highly aggressive myeloid neoplasms. Our goal is to comprehensively test this hypothesis, and, importantly, to reveal the underlying molecular mechanisms. Therefore, the three principal aims of this research proposal are: (1) To characterize the functional effects of mono- and biallelic TP53 mutations using novel in vitro model systems, (2) To elucidate the underlying molecular mechanisms of clonal expansion and malignant transformation induced by mono- and bi-allelic TP53 mutations, and (3) To study the functional impact of mono- and bi-allelic TP53 mutations on clonal expansion and malignant transformation of pre-leukemic hematopoietic stem and progenitor cells in vivo.We will combine newly generated in vitro model systems and superior in vivo mouse models of TP53-mutant clonal hematopoiesis with comprehensive and rigorous functional and mechanistic analyses allowing us to test this hypothesis to an unprecedented degree. Unraveling the molecular mechanisms of the putative dissociation of the functional effects of mono- vs. biallelic TP53 mutations would not only provide novel insights into fundamental p53 pathobiology but might also give impetus to the rational design of novel and innovative therapies based on the allelic configuration of TP53. Importantly, our findings will likely have broad implications for cancer biology beyond leukemogenesis given the high degree of conservation of p53 function among mammalian tissues.
Amount: CHF 524,000
Funding type: research
Funder scheme: Project funding
Start date: 2021-09-01
End date: 2026-08-31
Institutions: University of Zurich, University of Zurich – ZH
Subfield: Hematology
Field: Medicine
Funded outputs count: 2
Funder award ID: 197562
OpenAlex ID: G144614538